#ASH22: Adicet touts longer-term CR data after ASCO win
NEW ORLEANS — Adicet Bio is back with fresh data from its cell therapy candidate.
Adicet’s newest results are from its Phase I trial investigating ADI-001, an off-the-shelf gamma-delta CAR-T cell therapy. The company looked at 16 patients across multiple indications in relapsed or refractory B-cell non-Hodgkin’s lymphoma, double the number from its June readout at ASCO.
The update captures readouts through Dec. 5, and Adicet reported a 75% overall response rate and 69% complete response rate across four different dose levels and specific tumors that the patients had. That’s similar to the ASCO data, and could appease stock market analysts who had questioned the therapy’s long-term potential.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
